{"entity":{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","aka":[],"tldr":"A phase 3 trial of Melphalan flufenamide, Pomalidomide and Dexamethasone in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.","summary":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide is a phase 3 interventional study registered as NCT03151811 by Oncopeptides AB, with 495 participants recorded, started 2017-06-12 and due to reach its primary completion in 2021-02-03. Interventions recorded: Melflufen, Pomalidomide, Dexamethasone. Conditions recorded: Multiple Myeloma.\n\nLinked to the drug Melphalan flufenamide because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03151811","url":"https://clinicaltrials.gov/study/NCT03151811"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["melflufen","pomalidomide","dexamethasone"],"companies":["oncopeptides"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03151811","phase":"3","setting":"A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide","sponsor":"Oncopeptides AB","started":"2017-06-12","startedType":"actual","yearReported":2022,"enrolled":495,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Arm A: Melflufen+Dexamethasone","n":246,"value":6.83,"note":"95% CI 4.96 to 8.54; Figures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication"},{"name":"Arm B: Pomalidomide+Dexamethasone","n":249,"value":4.93,"note":"95% CI 4.24 to 5.72"}],"p":"0.0311","source":"https://clinicaltrials.gov/study/NCT03151811?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Arm A: Melflufen+Dexamethasone","n":246,"value":20.24,"note":"95% CI 15.84 to 24.15; Figures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication"},{"name":"Arm B: Pomalidomide+Dexamethasone","n":249,"value":23.98,"note":"95% CI 18.92 to 27.86"}],"source":"https://clinicaltrials.gov/study/NCT03151811?tab=results"},{"endpoint":"Overall Response Rate (ORR)","unit":"participants","arms":[{"name":"Arm A: Melflufen+Dexamethasone","n":246,"value":80,"note":"Figures from the ClinicalTrials.gov results section (first posted 2022-07-27), not from a publication"},{"name":"Arm B: Pomalidomide+Dexamethasone","n":249,"value":67}],"source":"https://clinicaltrials.gov/study/NCT03151811?tab=results"}]},"route":"/trials/nct03151811/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/"}]}}